Veracyte, Inc. (VCYT) News
Follow Veracyte, Inc. (VCYT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 25 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (G
NEWS | Sep 29, 2026, 12:09 PM UTC
L
Weekly Recap: Decipher studies at ASTRO 2026 and ARKG buys Veracyte, Inc.
Veracyte, Inc. (NASDAQ:VCYT) will showcase eight Decipher-focused studies, including Decipher Prostate Genomic Classifier data, at ASTRO 2026 in Boston, while ARK Genomic Revolution ETF (ARKG) boosted its biotech stake w
EQUITY | Sep 28, 2026, 11:06 AM UTC
L
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and likelihood of benefiting from treatment intensificationSOUTH SAN FRANCISCO
NEWS | Sep 25, 2026, 09:21 PM UTC
L
VCYT: Acquisition and innovation drive portfolio growth, with strong test performance and expanding market reach
The event highlighted a strategic acquisition to expand the bladder cancer portfolio, strong growth in Decipher and Afirma tests, and the launch of new products like Prosigna and TrueMRD. Operational synergies, robust ev
MNA | Sep 15, 2026, 12:49 PM UTC
L
Veracyte Price Target Maintained With a $66.00/Share by Freedom Capital Markets
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 12:05 PM UTC
L
VCYT: Acquisition-driven expansion, strong test growth, and robust evidence fuel portfolio and market leadership
The discussion highlighted a strategic acquisition to expand the bladder cancer portfolio, strong growth in Decipher and Afirma tests, and robust evidence generation supporting clinical adoption. Financial outlook remain
MNA | Sep 15, 2026, 12:01 PM UTC
L
Veracyte Acquires Convergent Genomics
By Katherine HamiltonVeracyte acquired Convergent Genomics, a bladder cancer treatment company, in a deal worth up to $180 million.The cancer diagnostics company said Monday that the deal will add Convergent's proprietar
NEWS | Sep 14, 2026, 08:41 PM UTC
H
Veracyte Acquires Convergent Genomics for $150 Million Cash Plus Up to $30 Million Earnout
Veracyte entered into an Agreement and Plan of Merger to acquire Convergent Genomics, adding the UroAmp test and urine tumor DNA technology to its portfolio. The deal closed on September 14, 2026, with $150 million paid
MNA | Sep 14, 2026, 08:13 PM UTC
H
Veracyte Contemplated Oper Expenses of Convergent in 2026 Adj EBITDA Guidance and Isn't Updating at This Time >VCYT
Veracyte Contemplated Oper Expenses of Convergent in 2026 Adj EBITDA Guidance and Isn't Updating at This Time >VCYT
EARNINGS | Sep 14, 2026, 08:10 PM UTC
H
Veracyte Acquires Convergent Genomics In $150M Deal, With Up To $30M Milestone Payments
Veracyte, Inc. (NASDAQ: VCYT ), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary t
LIVE | Sep 14, 2026, 08:07 PM UTC
L
Veracyte: Acquisition Includes $150 M in Upfront Cash and Up to $30 M in Additional Cash Tied to Key Milestones >VCYT
Veracyte: Acquisition Includes $150 M in Upfront Cash and Up to $30 M in Additional Cash Tied to Key Milestones >VCYT
MNA | Sep 14, 2026, 08:06 PM UTC
L
VCYT - Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
VCYT - Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
NEWS | Sep 14, 2026, 08:05 PM UTC
L
UBS maintains Buy on Veracyte; price target raised to $65
UBS maintains a Buy rating on Veracyte and raises its price target to $65.00 per share from $52.00, per Benzinga via TradingView News.
EQUITY | Sep 09, 2026, 06:11 PM UTC
L
Veracyte to participate in Morgan Stanley Global Healthcare Conference fireside chat
Veracyte announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, Sept. 15, 2026 at 7:00 a.m. Easter time.
EQUITY | Sep 01, 2026, 08:07 PM UTC
L
Veracyte to participate in Morgan Stanley Global Healthcare Conference
Veracyte says it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Sep 01, 2026, 08:06 PM UTC
H
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 300 points on Friday. Shares of Apple Inc (NASDAQ: AAPL ) fell sharply in pre-market trading after the company posted results for th
EARNINGS | Jul 31, 2026, 12:03 PM UTC
H
VCYT PT Raised to $69
VCYT price target raised to $69
EQUITY | Jul 31, 2026, 11:52 AM UTC
L
VCYT sees FY revenue growth 14-15%
VCYT forecasts revenue growth
EARNINGS | Jul 30, 2026, 08:45 PM UTC
H
MYGN -29%, RBLX -11.6%, FLGT -10.7%, VCYT -9.8%, SYK -9.5%, ALHC -8.6%, COIN -6.5%, RDDT -5.8%, GSIT -5.3%, IR -3.1% after results
MYGN -29%, RBLX -11.6%, FLGT -10.7%, VCYT -9.8%, SYK -9.5%, ALHC -8.6%, COIN -6.5%, RDDT -5.8%, GSIT -5.3%, IR -3.1% after results
EARNINGS | Jul 30, 2026, 08:15 PM UTC
L
VCYT Veracyte RESULTS: Q2, Q2 REV $150.3M vs. EST $144.6M, Q2 ADJ operating expenses $70M, Q2 Net Income $25.5M, Q2 gross margin 72%, Veracy
VCYT Veracyte RESULTS: Q2, Q2 REV $150.3M vs. EST $144.6M, Q2 ADJ operating expenses $70M, Q2 Net Income $25.5M, Q2 gross margin 72%, Veracyte Earnings Notes:, Outlook FY REV $590-596M vs. EST $586.4M
EARNINGS | Jul 30, 2026, 08:09 PM UTC
L
Veracyte Raises FY2026 Sales Guidance from $582.000M-$592.000M to $590.000M-$596.000M vs $586.445M Est
Veracyte (NASDAQ: VCYT ) raises FY2026 sales outlook from $582.000 million-$592.000 million to $590.000 million-$596.000 million vs $586.445 million estimate.
EARNINGS | Jul 30, 2026, 08:07 PM UTC
L
VCYT - Veracyte Announces Second Quarter 2026 Financial Results
VCYT - Veracyte Announces Second Quarter 2026 Financial Results
EARNINGS | Jul 30, 2026, 08:05 PM UTC
L
VCYT - Veracyte to Participate in Upcoming Investor Conferences
VCYT - Veracyte to Participate in Upcoming Investor Conferences
EQUITY | Jul 28, 2026, 08:06 PM UTC
L
VCYT Initiated Overweight W/$66.00 PT at Piper Sandler
VCYT Initiated Overweight W/$66.00 PT at Piper Sandler
EQUITY | Jul 15, 2026, 11:47 AM UTC
L
VCYT new Overweight W/ $66 PT @ Piper
VCYT new Overweight W/ $66 PT @ Piper
EQUITY | Jul 15, 2026, 11:26 AM UTC